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Microglia, the parenchymal tissue macrophages in the brain, surround amyloid plaques in brains of individuals with
Alzheimer’s disease (AD) but are ineffective at clearing amyloid to mitigate disease progression. Recent studies in mice
indicate that microglia are derived exclusively from primitive yolk sac hematopoiesis and self-renew without contribution
from ontogenically distinct monocytes/macrophages of definitive adult hematopoietic origin. Using a genetic fate-mapping
approach to label cells of definitive hematopoietic origin throughout life span, we discovered that circulating monocytes
contribute 6% of plaque-associated macrophages in aged AD mice. Moreover, peripheral monocytes contributed to a higher
fraction of macrophages in the choroid plexus, meninges, and perivascular spaces of aged AD mice versus WT control mice,
indicating enrichment at potential sites for entry into the brain parenchyma. Splenectomy, which markedly reduced circulating
Ly6Chi monocytes, also reduced abundance of plaque-associated macrophages of definitive hematopoietic origin, resulting
in increased amyloid plaque load. Together, these results indicate that peripherally derived monocytes invade the brain
parenchyma, targeting amyloid plaques to reduce plaque load.

Introduction

In Alzheimer’s disease (AD), impaired clearance of amyloid β (Aβ)
peptide results in its extracellular accumulation and concentration-dependent aggregation into amyloid plaques with neuronal
toxicity (1). Microglia, the parenchymal tissue macrophages in the
brain, are derived from yolk sac myeloid precursors via primitive
hematopoiesis (2) and self-renew without contribution from circulating monocytes (3, 4). Microglia degrade Aβ and phagocytose
amyloid material but have been variously characterized as dysfunctional owing to amyloid engorgement (5), dispensable for progression of plaque pathology (6), or as having a limited role in enveloping amyloid plaques to limit local Aβ diffusion and neurotoxicity
with advanced AD (7, 8). Consequently, there has been tremendous
interest in understanding whether ontogenically distinct peripheral
monocytes, i.e., cells derived from definitive hematopoiesis, cross
the blood-brain barrier to reinforce microglial function.
Earlier studies have indicated that peripheral monocytes trafficked into the AD brain parenchyma (9, 10); but these observations were confounded by blood-brain barrier disruption induced
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by irradiation or chemotherapeutic regimens (9). These experimental interventions were determined to be independently sufficient to allow entry of peripheral myeloid cells into the brain (11),
regardless of plaque pathology or age (9, 12). Findings of studies
implicating recruitment of peripheral monocytes based on cellular markers (13, 14) were subsequently noted to be confounded
based on gene expression changes observed in these markers in
disease-associated microglia in AD (15–18). Recent attempts to
avoid these experimental pitfalls through a parabiosis approach did
not demonstrate recruitment of peripheral monocytes; however,
these studies were limited to a short 4-week observation window
(19). Contemporary fate-mapping approaches have used tamoxifen-induced differential pulse labeling of cells of adult hematopoietic origin (via the CCR2 promoter; ref. 20) in the 5XFAD
mouse model, which is characterized by rapid plaque growth (21).
CCR2 promoter–driven reporter expression was observed in blood
and splenic Ly6chi monocytes, but not in the brain parenchyma,
suggesting that peripheral monocytes did not contribute to brain
microglial populations in this model. However, given the short
half-life of circulating monocytes (24–48 hours; refs. 22, 23), this
intermittent pulse-labeling strategy is expected to be transient,
with rapid disappearance of labeled circulating monocytes upon
cessation of tamoxifen treatment, resulting in reduced sensitivity for detection of gradual monocyte invasion of the brain compared with a continuous labeling strategy. Alternate approaches to
addressing recruitment of peripheral monocyte–derived cells, such
as the CXCR4erT2Cre-based fate-mapping strategy in the setting
of stroke (24), are not suitable owing to expression of CXCR4 in
1

RESEARCH ARTICLE

The Journal of Clinical Investigation  
Figure 1. Fate mapping demonstrates an
increased contribution of adult hematopoiesis-derived cells to CD68+ macrophages in the
choroid plexus and perivascular space in APP/
PS1 mice. Representative images demonstrating
GFP expression in CD68+ cells in WTmTmG;Flt3-Cre
and APP/PS1mTmG;Flt3-Cre mice, between 10 and
17 months of age, in the (A) choroid plexus, (C)
perivascular space, and (E) meninges, (B, D, and
F) with quantitation of GFP expression in this cell
population in the respective populations. Scale
bar: 20 μm (A, C, and E). n = 7–8/group. *P < 0.05,
t test.

microglia with amyloid pathogenesis (15, 16, 25). Toward this end,
we utilized a fate-mapping approach that constitutively labels
monocytes via the Flt3 promoter (26) throughout the life span of
the animal. We chose the APP/PS1 mouse model of AD because
it recapitulates the clinical characteristics of slow plaque development (27), which is more reflective of human AD pathogenesis and
may provide a broader time window to allow monocyte entry.

Results

We generated male APP/PS1mTmG;Flt3-Cre and littermate WTmTmG;Flt3-Cre
mice with Flt3-Cre–driven expression of a dual-fluorescence mTmG
reporter. Flt3 is solely expressed in all cells of definitive hematopoietic lineage (in fetal liver, adult bone marrow, and spleen) and not in
yolk sac–derived microglia (3). Circulating monocytes (Ly6GloCD11b+CD115+) demonstrated robust Cre-mediated GFP labeling
(Supplemental Figure 1, A and B; supplemental material available
online with this article; https://doi.org/10.1172/JCI152565DS1),
as predicted by expression of Cre via the Flt3 promoter. Flow cytometric immunophenotyping of cell surface markers in brain macrophage isolates from mice of more than ≥10 months of age revealed
GFP expression in CD45hiCD11b+ cells (Supplemental Figure 2, A
and C) that likely included perivascular, meningeal, and choroid
plexus macrophages, all of which are known to be maintained,
in part, by contributions from adult definitive hematopoiesis-derived cells (4). GFP expression was also noted in a small fraction
of CD45intCD11b+ cells (Supplemental Figure 2, A and D). Importantly, while we did not detect an increase in GFP+ cells among all
2

CD45+ cellular population (Supplemental Figure 2, A and B), there
was a trend toward increased GFP expression in this CD45intCD11b+
population (Supplemental Figure 2, A and D) in APP/PS1 mice compared with controls. To ascertain the location and characteristics of
GFP+ cells, we employed immunohistochemistry, a gold-standard
technique for examining the regional distribution of macrophage
and microglia populations (4).
Histologic examination of brains from aged APP/PS1mTmG;Flt3-Cre
and WTmTmG;Flt3-Cre mice (≥10 months of age) revealed GFP-labeled
CD45+ hematopoietic cells in the choroid plexus, perivascular spaces,
and meninges in WT mice (Supplemental Figure 3, A and B, and Supplemental Figure 4, A–F). We found a significant increase in GFP-labeled CD45+ (S4A-F) and GFP-labeled CD68+ cells (Figure 1) in the
choroid plexus (choroid plexus macrophages) and perivascular spaces
(perivascular macrophages) in APP/PS1 mice as compared with WT
controls. Notably, GFP+ cells expressing CCR2 were significantly increased in APP/PS1 mice in the choroid plexus, perivascular
spaces, and meninges (meningeal macrophages; Figure 2), as compared with WT controls, indicating their peripheral monocyte origin.
These data point to an increased appearance of adult hematopoiesis-derived monocytes/macrophages at these known transit points
that permit cellular trafficking into the brain parenchyma (28).
GFP-expressing cells were observed adjacent to amyloid
plaques (stained with X-34) in all aged APP/PS1 mice (>10 months
of age; Figure 3B and Supplemental Table 1), but they were not
detected in WT brain parenchyma (Figure 3A) or in 6-month old
APP/PS1 mice (Supplemental Table 1) at a stage prior to develop-
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Figure 2. Peripheral monocyte–derived cells are
increased in the choroid plexus, perivascular space,
and meninges of APP/PS1 mice. Representative
images demonstrating GFP+Ccr2+ cells in WTmTmG;Flt3-Cre
and APP/PS1mTmG;Flt3-Cre mice, between 10 and 17
months of age, in the (A) choroid plexus, (C) perivascular space, and (E) meninges, (B, D, and F) with quantitation of GFP+Ccr2+ cells in the respective locations.
Boxed regions in A, C, and E are shown at higher
magnification in insets. Scale bar: 10 μm (inset); 20
μm. n = 3–4/group. *P < 0.05, (B and F) t test and (D)
permutation testing (see Methods).

ment of significant plaque pathology (27). Importantly, GFP-expressing cells were not observed elsewhere in the brain parenchyma of APP/PS1 mice, indicating that these cells home in to the
amyloid plaques. GFP+ cells expressed Iba1 (Figure 3, C–F), CD11b
(Figure 3, G–J), and CD68 (Figure 3, K–N) and demonstrated
the lack of expression of astrocyte (GFAP) and neuronal (NeuN)
markers (Supplemental Figure 5). These findings indicate that
the plaque-associated peripherally derived GFP+ monocyte-derived cells had acquired characteristics of macrophages. Because
Flt3-mediated Cre expression also labels T and B lymphocytes,
neutrophils, and NK cells (29), we looked for the presence of these
markers in GFP-expressing cells (Supplemental Figures 6–9).
While we detected a few GFP+ B and T cells in the choroid plexus
in both genotypes, consistent with the presence of these cells in
normal physiology (18) and the presence of neutrophils and NK
cells in the choroid plexus of APP/PS1 mice, plaque-associated
GFP+ cells did not bear markers for any of these cell types.
We observed that amyloid material colocalized with plaque-
associated GFP+ cells (Figure 3O), suggesting that monocyte-derived macrophages were intimately interacting with the amyloid
plaque. Quantitative examination of APP/PS1 brains revealed that
the plaque-associated GFP-expressing cells constitute 5.9% of all

CD11b+ cells, 4.8% of CD68+ cells, and 2.2% of all Iba-1–expressing
cells (Table 1 and Supplemental Table 1). There was a strong correlation between plaque load and presence of GFP+ periplaque cells (Figure 3, P–R), indicating the extent that plaque pathology may influence
the homing signal for these recruited cells. To rule out the possibility
that the plaque-associated GFP+ peripheral monocytes are observed
in APP/PS1 brains because of previously uncharacterized expression
of Flt3 in this milieu, we examined expression of FLT3 protein. We did
not find any evidence to support FLT3 expression in WT cortex or its
activation in aging mice (Supplemental Figure 10).

Table 1. Contribution of GFP+ cells to cellular populations
in the brain parenchyma
Group
GFP+/Iba1+
GFP+/CD11b+
GFP+/CD68+

WT mice

APP/PS1 mice

0%
0%
0%

2.16 ± 0.44%
5.87 ± 1.05%
4.77 ± 0.64%

All are shown as the mean ± SEM. For WT and APP/PS1 mice, numbers
represent the cell type as a fraction of the total cell population.
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Figure 3. Fate mapping demonstrates
peripheral monocyte–derived cells
adjacent to amyloid plaques in the brain
parenchyma of APP/PS1 mice. (A and B)
Representative cortical sections from aged
WTmTmG;Flt3-Cre (n = 5) and APP/PS1mTmG;Flt3-Cre
mice (n = 8) demonstrating that GFP+ cells
(A) are not detected in the WT brain parenchyma and (B) are seen adjacent to X-34–
stained amyloid plaques in APP/PS1 mice.
White arrows point to a GFP+ cell in the
perivascular space in WTmTmG;Flt3-Cre brain in
A and to GFP+ cells adjacent to X34-labeled
amyloid plaques in B. Scale bar: 250 μm.
(C–N) Representative cortical sections from
aged APP/PS1mTmG;Flt3-Cre mice demonstrating
X-34–stained plaque (with DAPI-stained
nuclei as shown in C, G, and K; plaque is
outlined) (D, H, and L) with GFP expression,
(E and F) which colocalizes with a microglial
marker, Iba-1; (I and J) with CD11b, a marker
for activated microglia; and (M and N) with
CD68, a marker for phagocytic cells also
present on microglia. Scale bar: 10 μm.
Dotted lines outline amyloid plaques. (O)
A GFP+ cell adjacent to amyloid plaque
demonstrating colocalization with Aβ (red).
Dotted lines outline amyloid plaques. Scale
bar: 5 μm. (P–R) Correlation between the
density of GFP+ cells expressing (P) Iba-1, (Q)
CD11b, and (R) CD68 in the cortex and the
amyloid plaque load detected by X-34 staining. Pearson’s coefficient of correlation, R2 is
shown with P < 0.001.

Further characterization of plaque-associated GFP+ cells
demonstrated that these cells coexpressed macrophage and
microglial markers such as CD45 and TREM2, a microglial protein
implicated in AD pathogenesis (Supplemental Figure 11 and ref.
19). These cells were distinct from the nonplaque-associated GFP+
macrophages, as they lacked expression of CD206 (Supplemental
Figure 11), a recently described marker enriched in nonparenchymal macrophages in the mouse brain (4). Indeed, we confirmed
GFP expression in CD206+ choroid plexus macrophages and perivascular macrophages from both genotypes (Supplemental Figure
12), indicating an adult (definitive) hematopoietic contribution to
this population (4). Interestingly, GFP+ plaque-associated cells lose
expression of Ccr2 (which is observed in GFP+ cells in the perivascular spaces, meninges, and choroid plexus; Supplemental Figure 13)
and express Hexb (Supplemental Figure 14), a microglia-enriched
transcript (30), which is also observed to be expressed in engrafted monocyte-derived macrophages in the brain parenchyma in the
setting of experimental microglial ablation (31). Moreover, GFP+
cells in the brain parenchyma do not express Tmem119 (Supplemental Figure 15), a microglia-enriched transcript that is detectable in
APP/PS1 brains (Supplemental Figure 15) but downregulated in
the 5XFAD model of accelerated amyloid pathogenesis (30). Taken together, these data suggest that peripheral monocyte–derived
amyloid plaque–associated cells are a unique cellular population.
4

Previous studies have demonstrated that the spleen contributes to definitive hematopoiesis in mice (32) and acts as a reservoir of monocytes for sustained release into the circulation with
ongoing inflammatory stimuli (33). Indeed, splenic hypertrophy
was observed in a triple-transgenic AD model (34). Furthermore,
in the post–myocardial infarction state, the spleen was demonstrated to be a major source of circulating Ly6chi monocytes
(35, 36), a monocyte subset with high potential of migration to
tissues (37). Indeed, splenectomy in the face of chronic stress
attenuates inflammatory cell infiltration in the failing heart (38),
in dystrophic muscle (39), after stroke (40), and in abdominal
aortic aneurysms (41). To determine the functional contribution
of circulating monocytes to amyloid plaque pathogenesis, we
performed splenectomy on male APP/PS1mTmG;Flt3-Cre mice. Four
months after splenectomy, we observed an approximately 50%
reduction in GFP+ cells adjacent to the amyloid plaques (Figure 4, A–C), suggesting that elimination of the splenic reservoir
reduced the abundance of plaque-associated macrophages of
definitive hematopoiesis origin. This result also suggests that the
GFP+ macrophages in the brain parenchyma of APP/PS1 mice
were peripherally derived macrophages, rather than locally proliferating GFP+ macrophages. Notably, splenectomy did not alter
the total population of periplaque CD11b+ cells, irrespective of
the plaque size (Figure 4D).
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Figure 4. Splenectomy results in reduced
monocyte-derived periplaque macrophages. (A) Representative cortical
sections from APP/PS1mTmG;Flt3-Cre mice
subjected to splenectomy at 5.5 months
of age and sacrificed at 9.5 months of
age, demonstrating fewer GFP+CD11b+
cells next to amyloid plaques stained
with X-34. Areas boxed by dotted lines
are shown at higher magnification on the
right. (B) Density of GFP+ cells in the brain
parenchyma and (C) quantitation of GFP+
cells as a fraction of CD11b+ plaque-associated cells in mice from A. (D) Abundance of CD11b+ cells adjacent to amyloid
plaques stratified by size in mice from A.
n = 6 after splenectomy; n = 5 after sham
procedure. *P < 0.05, t test.

Given that Flt3-Cre is expressed via the Y chromosome (29),
which precludes direct examination of the fate-mapping reporter
system in females, we focused our analyses on evaluation of effects
of splenectomy on amyloid pathogenesis in female mice. Splenectomy resulted in a significant reduction in circulating Ly6chi
monocytes (Figure 5, A and B) and neutrophils (2,79,501 ± 21,119
cells/mL [mean ± SEM] after splenectomy vs. 23,71,722 ± 5,40,631
cells/mL [mean ± SEM] in sham; n = 9–12; P = 0.0002 by t test),
which were not recruited into the AD brain parenchyma (as shown
in Supplemental Figure 8). Notably, splenectomy led to a modest
but significant increase in HJ3.4–labeled amyloid plaque as well as
in X-34–stained compact plaque in the hippocampus (Figure 5, C
and D), as compared with that in sham controls. Splenectomy also
resulted in significant increases in soluble and guanidine-extractable Aβ42 in the cortex and guanidine-extractable Aβ40 and Aβ42
in the hippocampus (Figure 5, E–H). Taken together, these data
point to a functional role for circulating monocyte-derived macrophages in limiting amyloid plaque pathogenesis.

Discussion

Our data provide strong evidence that peripheral monocytes enter
the AD brain and specifically home in to amyloid plaques. The
Flt3-based fate-mapping strategy overcomes the limitations of
prior approaches by the continuously renewed expression of the
reporter in circulating monocytes in a mouse model with slower plaque growth that mimics the clinical evolution of pathology
in AD. This may explain why these cells were missed in recently reported fate-mapping studies that selectively labeled cells
with limited life spans (21). While the contribution of peripheral
monocyte–derived macrophages to the total activated microglial/macrophage population may appear small (Table 1), it is likely that recruitment is a dynamic and ongoing process, evidenced
by the increased appearance of peripheral cells at entry points to
the brain (Figures 1 and 2 and Supplemental Figure 4). Moreover,

unlike dysfunctional microglia in aged APP/PS1 mice, which can
only renew through in situ proliferation, peripherally derived macrophages have a theoretical advantage of taking up amyloid plaque
and, if toxicity occurs, being replaced by newly formed and fully
functional macrophages.
Importantly, these peripheral monocytes migrate selectively to amyloid plaques and take on microglial markers, suggesting recruitment of newly derived macrophages (31) to reinforce
microglial phagocytosis of amyloid material by virtue of being
naive to prior amyloid exposure. Indeed, our observations indicate that, while splenectomy does not eliminate the circulating
monocytes (with an ~53% reduction in circulating Ly6Chi monocytes (Figure 5, A and B), it induces a significant reduction in
plaque-associated monocyte-derived macrophages of approximately 50%, with increased amyloid plaque pathogenesis over a
period of 4 months (Figure 5, C–H). Given that splenectomy does
not alter the total number of activated (CD11b+) macrophages
associated with amyloid plaques (Figure 4D), these effects of
splenectomy are likely transduced by reduced monocyte recruitment into the brain parenchyma and are consistent with the
enhanced ability of newly recruited monocytes to degrade amyloid material as compared with the resident microglia exposed to
progressive amyloid pathology.
While our data do not address the potential for pleiotropic
mechanisms whereby splenectomy affects AD pathogenesis (42),
these observations point to the spleen as a potential reservoir for
sustained recruitment of these cells to the amyloid plaques, akin
to its role in other pathologic states (33, 38, 39, 41). Given multiple
lines of evidence pointing to a role of microglial dysfunction in
progression of AD pathogenesis, harnessing the role of peripheral
monocytes in limiting amyloid plaque pathogenesis has potential
therapeutic implications. Future studies will be required to assess
the kinetics of peripheral monocyte recruitment, survival, and
proliferation in the AD brain parenchyma to comprehensively
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Figure 5. Splenectomy reduces circulating myeloid cells and worsens amyloid pathology. (A and B) Flow cytometric phenotyping strategy A (after doublet exclusion was performed) for assessment of total white blood cells, monocytes (total, and separately as Ly6chi and Ly6clo), and neutrophils in APP/PS1
female mice 4 months after splenectomy compared with matched sham-operated controls. Grouped data for total monocytes and Ly6chi and Ly6clo monocytes is shown in B. n = 13 splenectomy; n = 9 sham. (C) Representative images of HJ3.4-stained (anti-Aβ antibody) (top) and X-34–stained compact amyloid plaques (bottom), (D) with quantitation of plaque load in the cortex and hippocampus by HJ3.4 staining (top) and X-34 staining (bottom) in female
APP/PS1 mice after splenectomy. n = 22 after splenectomy; n = 29 after sham procedure. Scale bar: 2.5 mm. (E–H) Quantitative assessment of Aβ40 and
Aβ42 levels in PBS-extracted and guanidine-extracted brain tissue from APP/PS1 mice subjected to splenectomy, as in D. n = 26 after splenectomy; n = 21
after sham procedure. *P < 0.05, (B) t test, except for comparison of Ly6chi monocytes by Wilcoxon’s rank-sum test; (D) t test, except for comparison of
X-34–stained plaques in hippocampus where a Wilcoxon’s rank-sum test was employed; (E) Wilcoxon’s rank-sum test; and (F–H) t test, except for comparison of Aβ42 levels in hippocampus in F, where Wilcoxon’s rank-sum test was employed.

assess the therapeutic potential of targeting this more accessible
cellular population (as compared with dysfunctional microglia
confined within the brain) in prevention and treatment of AD.

Methods

Fate-mapping studies. Male APP/PS1 mice [B6;C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax, ref. 43; The Jackson Laboratory, MMRRC stock no.
34928, maintained as C57BL/6 × C3H strain] carrying the mTomatolox-STOP-GFP cassette in the Rosa26 locus (The Jackson Laboratory,
stock no. 007676) (44) and Flt3 promoter–driven Cre transgene (as
it is expressed on the Y chromosome, ref. 29; RosamTmG:Flt3-Cre;
both mice were of the C57BL/6 strain) were generated. Littermate
male mice without the APP/PS1 transgene were employed as controls.
Cre-mediated excision of the mTomato cassette permits expression of
GFP exclusively in monocytes and is not observed in microglia, which
are derived from primitive hematopoietic precursors in the yolk sac.
Mice were sacrificed beginning at 6 months of age. After thorough
6

perfusion with PBS to remove circulating blood cells, one brain hemisphere was homogenized; mononuclear cells were isolated on a percoll gradient, as previously described (45); and live cells were evaluated using flow cytometry. The other hemisphere was used for histology.
Studies with splenectomy. Splenectomy and sham surgery was performed in 4.5-month-old female APP/PS1 mice (sham, n = 22; splenectomy, n = 29), following previously described surgical technique
(46). The animals were randomly assigned to the splenectomy procedure. Animals were anesthetized with induction of 3%–4% isoflurane
and maintained at 2%. A left-side dorsal incision was made lateral to
the spine, and the abdominal cavity was entered. The splenic blood
vessels were ligated, and the spleen was removed by transecting the
vessels just distal to the ligature. The skin incision was closed with
wound clips. Sham surgery was performed without ligating blood vessels and removing the spleen. Following surgery, mice were aged to
8.5 months (±0.5 months); blood was collected for flow cytometry,
and brains were harvested for histological analysis. Peripheral blood
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was used to perform flow cytometry experiments. Mice were cheek
bled via the facial vein, and red blood cells were lysed in lysis buffer
(BD Pharmlyse). Nucleated peripheral blood cells were then washed
once in PBS and incubated with appropriate antibodies in PBS containing 0.2% BSA on ice for 40 minutes and analyzed on a FACScan
flow cytometer (BD). Fluorescence data were analyzed by FlowJo, BD
FACS Diva analysis software. A mixture of the following mixture was
used for flow cytometry: FITC anti-mouse CD11b (Bioscience); APC
anti-mouse CD115 (Biolegend); APC-cy7 anti-mouse Ly6G (Biolegend); PE anti-mouse CD43 (Bioscience); PerCP-cy5.5 anti-mouse
Ly6c (Bioscience); and Pacific Blue anti-mouse CD45 (Biolegend). In
a separate cohort, splenectomy was performed in male APP/PS1 mice
carrying the mTomato-loxp-STOP-GFP cassette in the Rosa26 locus
and Flt3 promoter–driven Cre transgene at approximately 5.5 months
of age, and brains harvested at 9.5 months of age to assess for presence
of GFP+ cells adjacent to plaques.
Flow cytometry. Mice were cheek bled via the facial vein in 20 μL
EDTA (100 mM), and red blood cells were lysed in lysis buffer (BD
Pharmlyse). Nucleated peripheral blood cells were then washed once in
PBS and incubated with appropriate antibodies in PBS containing 0.2%
BSA on ice for 20 minutes, and cells were analyzed on a Fortessa or LSR
II (BD). Blood monocytes were stained by Pacific Blue anti-CD45 (30F11, Biolegend), APCCy7anti-CD11b (M1/70, Biolegend), APC antiCD115(AFS98, eBioscience), and PerCP anti-Ly6C (HK1.4, Biolegend).
Brain parenchymal cells were stained by Pacific Blue anti-CD45, APCCy7 anti-CD11b, and PECy7 anti-Ly6G (1A8, Biolegend). Flow cytometric data were analyzed by FlowJo, BD FACS Diva analysis software.
Immunohistochemistry. Brains were perfused, removed, and divided into hemispheres. One hemisphere was fixed for 24 hours in 4%
paraformaldehyde fixative in 0.1 M phosphate buffer (PB) (pH 7.4)
and then transferred to a solution containing 30% sucrose in 0.1 M PB
overnight. The tissue was then sectioned (30 μm) and immunostained
using antibodies delineated below. Brain sections were permeabilized
and blocked with 0.3% Triton X-100/ 3% dry milk in 0.01 M PBS for 30
minutes followed by incubation with primary antibodies overnight at
4°C and fluorescently labeled secondary antibodies at 37°C for 1 hour.
Primary and secondary antibodies employed are shown in Supplemental Table 2. GFP-tagged cells in the cortex, immunostained with Iba1
or CD11b, were counted in 6 equally spaced sections and expressed
as a percentage of the total number of Iba1 and CD11b cells per section. Slides were mounted and examined with a Nikon A1Rsi Confocal Microscope (Washington University Center for Cellular Imaging).
In control sections, the primary antibody was substituted by 3% dry
milk in 0.01 M PBS. GFP-tagged cells in the cortex (which are near the
amyloid plaques) were immunostained with Iba1, CD11b, or CD68;
counted in 3 equally spaced sections (180 μm apart), and expressed as a
percentage of the total number of Iba1-, CD11b-, and CD68-expressing
cells per section. For analysis of GFP-tagged cells in the choroid plexus,
meningeal, and perivascular structures, GFP+ cells were expressed as a
percentage of total CD45- or CD68-expressing cells.
Assessment of amyloid plaques. For X-34 staining, brain slices were
mounted on glass slides. Tissue was permeabilized with 0.25% Triton
for 30 minutes and stained with X-34 dissolved in a solution of 40%
ethanol in water, pH 10, for 20 minutes. Tissue was then rinsed in
distilled water and mounted. For amyloid staining, sections were permeabilized with 0.3% Tween-20 in Tris-buffered saline (TBS-T20)
for 10 minutes, and endogenous peroxidase activity was quenched by

a 10-minute treatment with 0.3% H2O2 solution in TBS. Tissue was
washed with TBS, blocked with 3% dry milk in TBS-T20 for 1 hour,
and incubated with anti-Aβ antibody (HJ3.4, 1:1000) antibody overnight. A fresh solution of streptavidin and horseradish peroxidase–
conjugated biotin (1:400, Vector Laboratories) was applied to tissue
for 90 minutes, followed by 0.025% 3-3′-diaminobenzidine tetrachloride in 0.25% NiCl and 0.05% H2O2 for 10 minutes. The plaque load
in 6 equally spaced sections (180 μm apart) per mouse were analyzed
and expressed as a percentage area of the cortex.
In situ hybridization by RNAscope technology. RNAscope Multiplex
Fluorescent Assay was combined with an immunofluorescence technique to detect transcripts for Tmem119, Ccr2, and Hexb, in concert
with imaging amyloid plaques (HJ3.4 antibody) and microglia (Iba1
antibody) in the mouse brain tissue. The RNA scope probe for the Ccr2
gene is Mus musculus chemokine (C-C motif) receptor 2 (Ccr2) mRNA
(catalog 501681, Advanced Cell Diagnostics Inc.). The RNA scope
probe for the Tmem119 gene is Mus musculus transmembrane protein
119 mRNA (catalog 472901-C2, Advanced Cell Diagnostics Inc.). The
RNA scope probe for the Hexb gene is Mus musculus hexosaminidase B
(Hexb) mRNA (catalog 314231-C1, Advanced Cell Diagnostics Inc.).
For fluorescent detection of mRNA signals, the fluorophores Opal 570
(1:2000) (Opal570 Reagent Pack, PN FP1488001KT, Akoya Biosciences) and Opal 520 (1:2000) (PN FP1487001KT, Akoya Biosciences)
were used. Based on the manufacturer’s fixed frozen tissue protocol,
mouse brain cryostat sections (30 μm thickness) postfixation, were
processed for target retrieval, protease treatment, hybridization with
target probes, preamplifier, amplifier, and Opal dye incubation (RNAscope Multiples Fluorescent Reagent Kitv2 Assay, ACD). Briefly, after
fixation in 4% paraformaldehyde in 0.1 M PB for 40 minutes, brain
sections were incubated in citrate buffer (10 nmol/L, pH 6) maintained at a boiling temperature (100°C–103°C) using a hot plate for
10 minutes, rinsed in deionized water, and immediately treated with
RNAscope protease III at 40°C for 30 minutes. Hybridization with
probes was performed for 2 hours at 40°C, followed by serial RNAscope Multiplex FFLv2 AMP steps at 40°C for 30 minutes, 30 minutes,
and 15 minutes, respectively. Opal Dye fluorophore was applied on the
sections at 40°C for 30 minutes. After RNAscope staining, the sections
were processed for fluorescence immunohistochemistry staining. The
RNAscope 3-plex Negative control probe and the RNAscope 3-plex
positive control probe were used to assess tissue RNA integrity, assay
procedure, and background signals. The Microscopic Imaging Nikon
A1Rsi Confocal Microscope (Nikon) was used for imaging and analysis. Analysis of GFP+CCR2+ cells in the choroid plexus and meningeal
and perivascular structures was performed in 4 sections/mouse and is
reported per unit area.
Biochemical assessment of Aβ levels. To measure Aβ, dissected
cortices or hippocampi were homogenized in PBS and then in 5 M
guanidine in TBS, pH 8.0 (to extract fibrillar and membrane bound
Aβ). Aβx–40 and Aβx–42 were assessed using mouse monoclonal capture
antibodies HJ2 (anti-Aβ35–40) and HJ7.4 (anti-Aβ37–42), respectively,
and a biotinylated central domain antibody, HJ5.1 (anti-Aβ13–28), was
used as the detecting antibody, followed by streptavidin-poly-HRP-40
(Fitzgerald Industries), as previously described (47). All ELISA assays
were developed using Super Slow ELISA TMB (MilliporeSigma), and
absorbance was read on a Bio-Tek Epoch plate reader at 650 nm. Standard curves were generated from synthetic human Aβ1–40 or Aβ1–42 peptides (American Peptide).
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Statistics. Results are expressed as mean ± SEM. Assumptions
of normality were examined by visual display and Shapiro-Wilk test.
Log transformation to natural base was applied for data that were not
normally distributed. Statistical differences were assessed with the
unpaired 2-tailed Student’s t test for 2 experimental groups (Prism,
version 5.2) for data that were normally distributed. For data that
failed normality testing, Wilcoxon’s rank-sum test was employed. For
data sets with a small sample size (Figure 2D), a permutation test was
used to compare the mean between 2 groups (independence_test () in
R package coin) (48). A 2-tailed P value of less than 0.05 was considered statistically significant.
Study approval. All animal studies were approved by the IACUC at
Washington University School of Medicine.
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